Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort

Hematol Oncol. 2020 Aug;38(3):412-414. doi: 10.1002/hon.2736. Epub 2020 Apr 23.

Tomas Jelinek^{1

2

3}, Tereza Popkova¹, Juraj Duras^{1

2}, Jana Mihalyova^{1

2}, Michal Kascak^{1

2}, Katerina Benkova^{1

2}, Hana Plonkova¹, Lucie Cerna^{1

2}, Zdenek Koristek^{1

2}, Michal Simicek^{1

2}, Roman Hajek^{1

2}

¹ Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
² Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
³ Faculty of Science, University of Ostrava, Ostrava, Czech Republic.

No abstract available

Keywords: Bcl-2; bortezomib; multiple myeloma; t(11;14); venetoclax.

Publication types